Dolores Grosso, DNP, CRNP

Contact Ms. Grosso

834 Chestnut Street
Suite 315
Philadelphia, PA 19107

(215) 955-8874
fax

Education
BSN: Thomas Jefferson University, Philadelphia, Pa. 1981

MSN: University of Pennsylvania, Philadelphia. Pa. 1986

CRNP: University of Pennsylvania, Philadelphia, Pa. 1995

Doctor of Nursing Practice, Thomas Jefferson University Philadelphia, Pa. 2009

Board Certifications
Acute Care Nurse Practitioner (ANCC)
CCRN Alumnus (AACN)

University Appointment
Research Instructor

Specialties
Medical Oncology: Allogeneic Hematopoietic Stem Cell Transplantation
Medical Oncology: Allogeneic Donor Selection
Medical Oncology: Hematologic Malignancies

Publications

Most recent Peer-reviewed Publications

1. Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft-versus-Graft Effects
2. A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation
3. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
4. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
5. Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
6. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
7. Cytoprotection in acute myelogenous leukemia (AML) therapy
8. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
9. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
10. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
11. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches
12. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML